سعر ليزبيرج بلس 40/25مجم 30 قرص 2025

Olmesartan 40 mg / hydrochlorothiazide 25 mg film-coated tablets, pack of 30 (3 strips of 10).

• Treatment of hypertension, to lower blood pressure; not indicated for initial therapy.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Adverse reactions reported more often than placebo (≥ 2%) included nausea, hyperuricaemia, dizziness and upper respiratory tract infection.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Hypersensitivity to any component of the product.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Anuria.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Do not co-administer aliskiren with this product in patients with diabetes.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Fetal toxicity (boxed warning): drugs acting directly on the renin-angiotensin system during the second and third trimesters reduce fetal renal function and increase fetal and neonatal morbidity and death; discontinue as soon as possible when pregnancy is detected.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Symptomatic hypotension may occur after initiation in volume- or salt-depleted patients (e.g. on high-dose diuretics); correct depletion before starting or start under close medical supervision.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Changes in renal function including acute renal failure can occur, particularly in patients whose renal function depends on the renin-angiotensin system (e.g. renal artery stenosis, severe heart failure, volume depletion); monitor renal function periodically.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Aliskiren / ACE inhibitors / other angiotensin receptor blockers (dual RAS blockade)AvoidDual blockade of the renin-angiotensin system increases the risk of hypotension, hyperkalaemia and changes in renal function including acute renal failure; avoid combined use, do not use aliskiren in patients with diabetes, and monitor blood pressure, renal function and electrolytes.DailyMed (U.S. National Library of Medicine)
• NSAIDs including selective COX-2 inhibitorsIn elderly, volume-depleted or renally impaired patients, NSAIDs with an angiotensin II receptor antagonist may deteriorate renal function, including possible acute renal failure, and may attenuate the antihypertensive effect; monitor renal function periodically.DailyMed (U.S. National Library of Medicine)
• LithiumIncreases in serum lithium concentrations and lithium toxicity have been reported with angiotensin II receptor antagonists; monitor serum lithium levels during concomitant use.DailyMed (U.S. National Library of Medicine)

• Fetal toxicity (boxed warning): drugs acting directly on the renin-angiotensin system during the second and third trimesters reduce fetal renal function and increase fetal and neonatal morbidity and death; discontinue as soon as possible when pregnancy is detected.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Because of the potential for adverse effects on the nursing infant, avoid use while nursing (discontinue nursing or the drug).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Olmesartan: Olmesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking its binding to the AT1 receptor.
• Hydrochlorothiazide: Promotes renal excretion of sodium and chloride, reducing intravascular volume.